Evidence map›Paper›PMID 40999521›Full record

ArticleJournal of cheminformatics2025

Cache: Utilizing ultra-large library screening in Rosetta to identify novel binders of the WD-repeat domain of Leucine-Rich Repeat Kinase 2.

Fabian Liessmann, Paul Eisenhuth, Alexander Fürll, Oanh Vu, Rocco Moretti, Jens Meiler

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fabian Liessmann *Institute for Drug Discovery, Leipzig University, 04103, Leipzig, Germany.
Paul Eisenhuth *Institute for Drug Discovery, Leipzig University, 04103, Leipzig, Germany.
Alexander Fürll *Institute for Drug Discovery, Leipzig University, 04103, Leipzig, Germany.
Oanh VuCenter for Structural Biology, Vanderbilt University, Nashville, TN, 37235, USA.
Rocco MorettiCenter for Structural Biology, Vanderbilt University, Nashville, TN, 37235, USA.
Jens MeilerInstitute for Drug Discovery, Leipzig University, 04103, Leipzig, Germany. jens@meilerlab.org.

Funding

Bundesministerium für Bildung und Forschung ScaDS.AIDeutsche Forschungsgemeinschaft 421152132
6 · The paper itself

Abstract

In this study, we present a pipeline for identifying novel ligands targeting the Tryptophan-Aspartate-Repeat domain 40 (WDR40) of Leucine-Rich Repeat Kinase 2 (LRRK2), a protein associated with Parkinson's disease, as part of the first Critical Assessment of Computational Hit-finding Experiments (CACHE) challenge, a blind benchmark experiment for drug discovery. Mutations in this protein are the most common genetic cause of familial Parkinson's disease, yet this target remains understudied. We conducted an ultra-large library screening (ULLS) of the Enamine REAL space using a newly developed evolutionary algorithm, RosettaEvolutionaryLigand (REvoLd), which allows for efficient screening of combinatorial compound libraries. The protocol involved refining the target structure with molecular dynamic simulations, identifying a binding site via blind-docking, and optimizing compounds through REvoLd, culminating in a manual selection amongst the top-scoring REvoLd hits. A single binder molecule was identified that derived from the combination of two Enamine building blocks. In the second round, derivatives of the hit compound were used as input for REvoLd to further sample within the Enamine REAL space. Ultimately, a total of five molecules were identified, from which three show a measurable dissociation constant K

Indexed as

CACHE challengeDrug discoveryLRRK2REvoLdRosettaUltra-large library screening

Identifiers

PMID40999521
PMCPMC12465524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.